专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015155513A1 DIAGNOSIS OF CANCER BY DETECTING DIMERIC IL-18 审中-公开
标题翻译：通过检测二维IL-18诊断癌症
公开(公告)号：WO2015155513A1
公开(公告)日：2015-10-15
申请号：PCT/GB2015/051052
申请日：2015-04-02
申请人： RANDOX LABORATORIES LTD
发明人： CHACKO, Alex , MCCONNELL, Ivan , FITZGERALD, Peter , LAMONT, John V.
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , G01N33/6869 , G01N2333/54 , G01N2800/52
摘要： The present invention describes methods for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, and comparing that level with the level in a normal control sample. The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.
摘要翻译：本发明描述了通过测量从受试者获得的样品中的二聚体IL-18的水平，并将该水平与正常对照样品中的水平进行比较来筛选受试者中癌症的方法。本发明还描述了通过测量从受试者获得的样品中的二聚体IL-18的水平来筛选受试者中的癌症的测定，由此提高的二聚体IL-18水平是癌症的指示。

2. 发明申请

WO2014060753A1 DIAGNOSIS AND RISK STRATIFICATION OF BLADDER CANCER 审中-公开
标题翻译：乳腺癌的诊断和风险分析
公开(公告)号：WO2014060753A1
公开(公告)日：2014-04-24
申请号：PCT/GB2013/052705
申请日：2013-10-16
申请人： RANDOX LABORATORIES LTD.
发明人： RUDDOCK, Mark W. , REID, Cherith N. , WILLIAMSON, Kate E. , EMMERT-STREIB, Frank , LAMONT, John V. , FITZGERALD, Peter
IPC分类号： G01N33/574
CPC分类号： G06F19/18 , G01N33/57407 , G01N33/57484 , G01N2333/4737 , G01N2333/4742 , G01N2333/475 , G01N2333/485 , G01N2333/523 , G01N2333/525 , G01N2333/5406 , G01N2333/5412 , G01N2333/5421 , G01N2333/545 , G01N2333/55 , G01N2333/70578 , G01N2333/70596 , G01N2333/7151 , G01N2333/7452 , G01N2333/928 , G01N2333/96433 , G01N2333/96494 , G01N2333/988 , G01N2400/00 , G06F19/00 , G06F19/24 , G16H50/30
摘要： The invention provides amethod of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by:i. identifying at least one sub-population group appropriate to the subject;ii. determining the level of one or more biomarkers selected according to the sub- population group in a sample obtained from the subject;iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, historyof benign prostate enlargement (BPE) or prescription ofanti-hypertensive, anti-platelet and/or anti- ulcer medication, and (B) determining the subject's stratified risk levelof serious disease by:v. determining the level of one or more biomarkers specific for one or more risk classifiers defined using Random Forest Classifiers (RFC), logistic regression or another appropriate systems biology or statistical approach in a sample obtained from the subject,vi. inputting each of the biomarker values into an algorithm or algorithms to produce an output value; and vii. correlating the output value with a stratified risk level of underlying serious disease, wherein the likelihoodof having bladder cancer is combined with the stratified risk level of having serious disease, wherein the risk of having bladder cancer and/or serious disease is categorised as: high-risk bladder cancer requiring immediate cystoscopy; low-risk bladder cancer requiring urgent cystoscopy; high- risk control requiring close evaluation and further investigation; or low-risk control requiring primary care monitoring.
摘要翻译：本发明提供了定义具有膀胱癌的受试者的可能性的方法，其包括以下步骤：（A）通过以下方式评估受试者患膀胱癌的可能性：i。识别适合该受试者的至少一个亚群体群体; ii。确定从受试者获得的样品中根据亚群体组选择的一种或多种生物标志物的水平; iii。将每个生物标记值输入到算法中以产生输出值; 和iv。将输出值与患有膀胱癌的患者的可能性相关联，其中根据吸烟习惯，性别，存在/不存在石头疾病，良性前列腺增生（BPE）或抗高血压症，血小板和/或抗溃疡药物，和（B）通过以下方式确定受试者的分层危险性严重疾病：确定使用随机森林分类器（RFC）定义的一个或多个风险分类器特定的一个或多个生物标志物的水平，逻辑回归或从受试者获得的样本中的其他适当系统生物学或统计学方法。将每个生物标记值输入算法或算法以产生输出值; 和vii。将输出值与潜在严重疾病的分层风险水平相关联，其中将膀胱癌的可能性与具有严重疾病的分层风险水平相结合，其中将膀胱癌和/或严重疾病的风险分类为：膀胱癌需要立即膀胱镜检查的风险; 低危膀胱癌需要紧急膀胱镜检查; 高风险控制需要进行密切的评估和进一步的调查; 或需要初级保健监测的低风险控制。

3. 发明申请

WO2010119286A1 ALZHEIMER'S DISEASE 审中-公开
标题翻译：阿尔茨海默氏病
公开(公告)号：WO2010119286A1
公开(公告)日：2010-10-21
申请号：PCT/GB2010/050621
申请日：2010-04-15
申请人： RANDOX LABORATORIES LTD , CORSI, Massimiliano , FITZGERALD, Stephen P. , LAMONT, John V. , INNOCENZI, Paul
发明人： CORSI, Massimiliano , FITZGERALD, Stephen P. , LAMONT, John V. , INNOCENZI, Paul
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.
摘要翻译：本发明涉及诊断受试者中的阿尔茨海默病（AD）的方法和确定AD患者预后的方法。首次描述了粘附分子P-选择素和L-选择蛋白作为生物标志物用于辅助AD诊断。本发明还描述了L-选择素，MCP-1，IL-1a，IL-8和IFN-α中的一种或多种的使用以帮助AD患者加速认知衰退（ACD）或缓慢认知衰退（SCD）的预后。

4. 发明公开

EP2909631A1 DIAGNOSIS AND RISK STRATIFICATION OF BLADDER CANCER 有权转让
标题翻译：诊断RISIKOSTRATIFIZIERUNG VON BLASENKREBS
公开(公告)号：EP2909631A1
公开(公告)日：2015-08-26
申请号：EP13783627.6
申请日：2013-10-16
申请人： Randox Laboratories Ltd.
发明人： RUDDOCK, Mark W. , REID, Cherith N. , WILLIAMSON, Kate E. , EMMERT-STREIB, Frank , LAMONT, John V. , FITZGERALD, Peter
IPC分类号： G01N33/574
CPC分类号： G16B20/00 , G01N33/57407 , G01N33/57484 , G01N2333/4737 , G01N2333/4742 , G01N2333/475 , G01N2333/485 , G01N2333/523 , G01N2333/525 , G01N2333/5406 , G01N2333/5412 , G01N2333/5421 , G01N2333/545 , G01N2333/55 , G01N2333/70578 , G01N2333/70596 , G01N2333/7151 , G01N2333/7452 , G01N2333/928 , G01N2333/96433 , G01N2333/96494 , G01N2333/988 , G01N2400/00 , G16B40/00 , G16H50/30
摘要： The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v. determining the level of one or more biomarkers specific for one or more risk classifiers defined using Random Forest Classifiers (RFC), logistic regression or another appropriate systems biology or statistical approach in a sample obtained from the subject, vi. inputting each of the biomarker values into an algorithm or algorithms to produce an output value; and vii. correlating the output value with a stratified risk level of underlying serious disease, wherein the likelihood of having bladder cancer is combined with the stratified risk level of having serious disease, wherein the risk of having bladder cancer and/or serious disease is categorised as: high-risk bladder cancer requiring immediate cystoscopy; low-risk bladder cancer requiring urgent cystoscopy; high-risk control requiring close evaluation and further investigation; or low-risk control requiring primary care monitoring.
摘要翻译：本发明提供了一种定义患有膀胱癌的受试者的可能性的方法，包括以下步骤：（A）通过以下步骤评估受试者患有膀胱癌的可能性：i。识别适合于该受试者的至少一个亚群体组; II。确定从所述受试者获得的样品中根据所述亚群体组选择的一种或多种生物标志物的水平; III。将每个生物标记值输入到算法中以产生输出值; 和iv。将输出值与患有膀胱癌的患者的可能性相关联，其中根据吸烟习惯，性别，存在/不存在石头疾病，良性前列腺增生病史（BPE）或抗高血压药物处方选择亚群体组，抗血小板和/或抗溃疡药物，和（B）通过以下方式确定受试者的严重疾病分层风险水平：v。确定一个或多个特定于使用随机森林分类器定义的风险分类器的生物标志物的水平 RFC），逻辑回归或从该主题获得的样本中的其他适当的系统生物学或统计学方法，vi。将每个生物标记值输入算法或算法以产生输出值; 和vii。将输出值与潜在严重疾病的分层风险水平相关联，其中膀胱癌的可能性与具有严重疾病的分层风险水平相结合，其中具有膀胱癌和/或严重疾病的风险被分类为：高膀胱癌需要立即膀胱镜检查; 需要紧急膀胱镜检查的低危膀胱癌; 高风险控制需要进行密切的评估和进一步的调查; 或需要初级保健监测的低风险控制。

5. 发明公开

EP2419738A1 ALZHEIMER'S DISEASE 有权
标题翻译：阿尔茨海默氏病的
公开(公告)号：EP2419738A1
公开(公告)日：2012-02-22
申请号：EP10714063.4
申请日：2010-04-15
申请人： Randox Laboratories Ltd.
发明人： CORSI, Massimiliano , FITZGERALD, Stephen P. , LAMONT, John V. , INNOCENZI, Paul
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.

6. 发明授权

EP2909631B1 DIAGNOSIS AND RISK STRATIFICATION OF BLADDER CANCER 有权转让
公开(公告)号：EP2909631B1
公开(公告)日：2019-07-24
申请号：EP13783627.6
申请日：2013-10-16
申请人： Randox Laboratories Ltd.
发明人： RUDDOCK, Mark W. , REID, Cherith N. , WILLIAMSON, Kate E. , EMMERT-STREIB, Frank , LAMONT, John V. , FITZGERALD, Peter
IPC分类号： G01N33/574

7. 发明授权

EP3129785B1 DIAGNOSIS OF CANCER BY DETECTING DIMERIC IL-18 有权
公开(公告)号：EP3129785B1
公开(公告)日：2019-02-27
申请号：EP15715807.2
申请日：2015-04-02
申请人： Randox Laboratories Ltd.
发明人： CHACKO, Alex , MCCONNELL, Ivan , FITZGERALD, Peter , LAMONT, John V.
IPC分类号： G01N33/574

8. 发明公开

EP3129785A1 DIAGNOSIS OF CANCER BY DETECTING DIMERIC IL-18 有权
标题翻译： DIAGNOSE VON KREBS DURCH NACHWEIS VON DIMEREM IL-18
公开(公告)号：EP3129785A1
公开(公告)日：2017-02-15
申请号：EP15715807.2
申请日：2015-04-02
申请人： Randox Laboratories Ltd.
发明人： CHACKO, Alex , MCCONNELL, Ivan , FITZGERALD, Peter , LAMONT, John V.
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , A61P35/00 , A61P35/04 , C07K14/54 , G01N33/53 , G01N33/57423 , G01N33/6869 , G01N2333/54 , G01N2800/52
摘要： The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.
摘要翻译：本发明还描述了通过测量从受试者获得的样品中二聚体IL-18的水平，从而提高水平的二聚体IL-18指示癌症，从而筛选受试者中的癌症。

9. 发明授权

EP2419738B1 ALZHEIMER'S DISEASE 有权
标题翻译： MORBUS ALZHEIMER
公开(公告)号：EP2419738B1
公开(公告)日：2016-03-30
申请号：EP10714063.4
申请日：2010-04-15
申请人： Randox Laboratories Ltd.
发明人： CORSI, Massimiliano , FITZGERALD, Stephen P. , LAMONT, John V. , INNOCENZI, Paul
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.
摘要翻译：本发明涉及诊断受试者中的阿尔茨海默病（AD）的方法和确定AD患者预后的方法。首次描述了粘附分子P-选择素和L-选择蛋白作为生物标志物用于辅助诊断AD。本发明进一步描述了L-选择素，MCP-1，IL-1α，IL-8和IFN-γ中的一种或多种的用途有助于加速认知衰退（ACD）或缓慢认知衰退（SCD）在AD患者

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式